Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975915 | 0.88 | CTSS (0.47) | CTSSCTSLCTSBADAM17NPC1 | |
| SCHEMBL28719272 | 0.88 | CTSS (0.47) | CTSSCTSLCTSBADAM17NPC1 | |
| SCHEMBL2913795 | 0.87 | CTSS (0.55) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1974652 | 0.86 | CTSB (0.51) | CTSSCTSLCTSBADAM17NPC1 | |
| SCHEMBL10332172 | 0.85 | CTSS (0.59) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL22041768 | 0.81 | CTSS (0.50) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL17007927 | 0.81 | CTSB (0.47) | CTSSCTSLCTSBADAM17NPC1 | |
| SCHEMBL28715383 | 0.81 | CTSS (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1975740 | 0.80 | CTSS (0.48) | CTSSCTSLCTSBADAM17NPC1 | |
| SCHEMBL22041903 | 0.79 | CTSS (0.47) | CTSSCTSLCTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2139854-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074867-A1 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | CTRL, PREP, CES1 | CTSS 81/4885CTSL 121/4885CTSB 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.